Triplex HIV, HCV, HBsAg

Product catalog summary

Overview: The document describes a rapid and effective screening test for three viral diseases: HIV, HCV, and HBsAg. It highlights the simplicity and speed of the test, which requires only a small sample of blood, serum, or plasma and provides results in 15 minutes.

Specifications: The test is referred to as Triplex and is identified by the reference number 1150025. It is produced by BIOSYNEX SA, located in Illkirch-Graffenstaden, France. The test kit includes 25 tests and pipettes for capillary blood sampling, with an expiration period of 18 months.

Procedure: The test involves three steps:

Step 1: Add 50μL of capillary or venous blood, or 25μL of serum or plasma into well S.
Step 2: Add 4 drops of diluent into well B.
Step 3: Wait 15 minutes before reading the result.

Interpretation: The results are interpreted based on the presence of lines at specific test points (T1, T2, T3) alongside a control line (C). Different combinations of lines indicate positive results for HIV, HCV, and HBsAg.

Context and Importance: The document emphasizes the significant public health challenge posed by these viral infections, particularly in Africa, where millions are affected by HIV and hepatitis viruses. It underscores the need for accessible screening and treatment to prevent chronic liver disease, cancer, and death.

Catalog excerpts

The precision of a laboratory, the flexibility of a mobile solution EFFECTIVE : Simultaneous screening of 3 viral diseases SIMPLE Only 50 yL of capillary blood or 25 yL of serum and plasma RAPID Results in 15 minutes VIROLOGY biosYnex EASY DIAGNOSTICS FOR LIFE

Open the catalog to page 1

Triplex HIV, HCV, HBsAg 35 million people in Africa are infected with the HIV virus, 16 million of whom have access to treatment and 2 million people are newly infected each year. In addition, in 2017, the World Health Organization (WHO) reports that 325 million people are living with chronic hepatitis B virus (HBV) or hepatitis C (HCV) infection. The report says that the majority (> 250 million) of these people do not have access to screening and treatment that could save their lives. As a result, millions of people are confronted with the risk of slow development towards chronic liver disease,...

Open the catalog to page 2

Triplex HIV, HCV, HBsAg

Triplex HIV, HCV, HBsAg

Catalog excerpts

All BIOSYNEX catalogs and technical brochures